CARLSBAD, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO)
(www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem
cell-based therapies and biomedical products, announced today that the second patient of the third cohort of the clinical trial for
Parkinson's disease was successfully transplanted with 70,000,000 ISC-hpNSC® cells.
The surgery, which was performed by a team of neurosurgeons at the Royal Melbourne Hospital in Melbourne, Australia, proceeded
without complications and the patient was discharged soon after.
"We are pleased to provide an update regarding the progress of our Parkinson's disease clinical trial," commented ISCO's
Executive Vice President and Chief Scientific Officer Russell Kern, PhD. "This is the second patient receiving the highest dose,
bringing the total to 10 patients transplanted with ISC-hpNSC® cells. Based on the available clinical data, we are confident that
the therapy is safe, well-tolerated, and can potentially improve the quality of life of the patients," he continued.
Six patients have now fully completed the study and entered the follow-up phase while two other patients have completed the
six-month evaluation. The treatment phase of the study will conclude following the dosing of the last two patients of the third
cohort, which ISCO plans to complete soon.
About the clinical study
The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted
into patients with moderate Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three
different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate-to-severe Parkinson's
disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals to evaluate
the safety and biologic activity of ISC-hpNSC®. A PET scan will be performed at baseline, as part of the screening assessment, and
at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will
be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and
other rating scales. An extension phase of the study will evaluate patients every 6 months for 5 additional years.
About Parkinson's disease
Parkinson's disease is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor
symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the
midbrain. Early in the course of the disease, the most obvious symptoms are movement-related. These symptoms include shaking,
rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with
dementia commonly occurring in the advanced stages of the disease, and depression as the most common psychiatric symptom.
Parkinson's disease is more common in people over the age of 50.
There are no approved treatments that restore the damaged dopaminergic neurons. Medications typically used in the treatment of
Parkinson's disease, levodopa and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and
dopaminergic neurons continue to be lost, the drugs eventually become ineffective, while at the same time frequently producing a
complication marked by involuntary writhing movements. There are over 10 million people afflicted by Parkinson's disease worldwide.
In 2013 Parkinson's disease resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.
About ISC-hpNSC®
International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived
from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that
have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in
rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels
following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and neuroregeneration to the
dying dopaminergic neurons of the recipient Parkinson's disease brain. Additionally, ISC-hpNSC® is safe, well tolerated and does
not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation
believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal
cord and the eye.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic,
homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders,
ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true
stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide
through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its
subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, clinical studies expectations (including timing and results), progress of
research and development, and other opportunities for the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any
statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or
commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital
resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that
affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
Russell Kern, PhD
Executive Vice President
Chief Scientific Officer
Phone: +1 760 940 6383
Email: ir@intlstemcell.com
